D.A. Davidson & CO. Sells 952 Shares of Zoetis Inc. $ZTS

D.A. Davidson & CO. decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 4.1% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 22,143 shares of the company’s stock after selling 952 shares during the quarter. D.A. Davidson & CO.’s holdings in Zoetis were worth $3,453,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently added to or reduced their stakes in the company. Nova Wealth Management Inc. bought a new position in Zoetis during the 1st quarter worth $25,000. 1248 Management LLC bought a new position in Zoetis during the 1st quarter worth $27,000. Saudi Central Bank acquired a new position in Zoetis in the first quarter valued at about $29,000. REAP Financial Group LLC raised its stake in Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock valued at $31,000 after purchasing an additional 131 shares in the last quarter. Finally, Cornerstone Planning Group LLC raised its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on ZTS shares. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Zoetis in a research note on Friday. Leerink Partnrs downgraded Zoetis from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 17th. Argus reaffirmed a “buy” rating and issued a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Leerink Partners cut Zoetis from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, UBS Group decreased their target price on Zoetis from $165.00 to $158.00 and set a “neutral” rating on the stock in a research report on Monday. Four analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $195.00.

Zoetis Stock Performance

NYSE:ZTS opened at $146.14 on Friday. The stock has a market cap of $64.77 billion, a P/E ratio of 25.15, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05. The stock’s 50-day moving average is $148.18 and its 200-day moving average is $153.50. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $184.40.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 5th. The company reported $1.76 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.14. The company had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same period in the previous year, the business posted $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Equities research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 2nd. Stockholders of record on Friday, October 31st will be issued a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a dividend yield of 1.4%. The ex-dividend date is Friday, October 31st. Zoetis’s payout ratio is 34.42%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.